sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• The suppressor of MEK null (sMEK1) protein is known for its pro-apoptotic activities.
• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
• Ovarian tumors rely on angiogenesis for survival and metastasis.

Purpose of the Study:

• To investigate the role of sMEK1 in angiogenesis, particularly in the context of ovarian tumor progression.
• To elucidate the molecular mechanisms by which sMEK1 affects endothelial cell function and tumor vascularity.
• To evaluate the potential of sMEK1 as an anti-angiogenic and anti-tumor therapeutic agent for ovarian cancer.

Main Methods:

• In vitro assays were used to assess the effects of sMEK1 on vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, migration, and capillary-like tubular structure formation.
• Western blot analysis was performed to examine the phosphorylation status of key signaling molecules in the PI3K/Akt pathway, including PLC-γ1, PDK1, eNOS, and HIF-1α.
• sMEK1's interaction with vascular endothelial growth factor receptor 2 (VEGFR-2) was investigated.
• A xenograft human ovarian tumor model was utilized to evaluate the in vivo effects of sMEK1 on tumor vascularity and growth.

Main Results:

• sMEK1 demonstrated significant anti-angiogenic properties by suppressing VEGF-induced endothelial cell proliferation, migration, and tube formation in vitro.
• sMEK1 inhibited the phosphorylation of downstream signaling components of the Akt pathway, including PLC-γ1, PDK1, eNOS, and HIF-1α, during ovarian tumor progression.
• The anti-angiogenic effect of sMEK1 was mediated through its binding to VEGFR-2, thereby suppressing the VEGFR-2-mediated PI3K/Akt/eNOS signaling pathway.
• In vivo studies showed that sMEK1 decreased tumor vascularity and significantly inhibited tumor growth in a xenograft human ovarian tumor model.

Conclusions:

• sMEK1 functions as a novel anti-angiogenic factor by inhibiting VEGFR-2-mediated PI3K/Akt/eNOS signaling.
• sMEK1 effectively suppresses endothelial cell function and angiogenesis, crucial processes in ovarian tumor development.
• These findings highlight sMEK1 as a promising therapeutic candidate for an anti-angiogenic and anti-tumor strategy in ovarian cancer treatment.